Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.

Jakubowski JA, Winters KJ, Naganuma H, Wallentin L.

Cardiovasc Drug Rev. 2007 Winter;25(4):357-74. Review.

PMID:
18078435
2.

Prasugrel for the treatment of patients with acute coronary syndrome.

Marzot F, Pengo V.

Vasc Health Risk Manag. 2009;5(1):321-4. Epub 2009 Apr 8. Review.

3.

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.

Niitsu Y, Jakubowski JA, Sugidachi A, Asai F.

Semin Thromb Hemost. 2005 Apr;31(2):184-94. Review.

PMID:
15852222
4.

[Prasugrel, a new thienopyridine].

Schrör K, Huber K.

Hamostaseologie. 2007 Dec;27(5):351-5. German.

PMID:
18060245
5.

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.

Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F.

J Thromb Haemost. 2007 Jul;5(7):1545-51. Epub 2007 Apr 19. Erratum in: J Thromb Haemost. 2007 Sep;5(9):1995.

6.

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

Mousa SA, Jeske WP, Fareed J.

Clin Appl Thromb Hemost. 2010 Apr;16(2):170-6. doi: 10.1177/1076029609355589. Review.

PMID:
20299391
7.

Prasugrel: a novel antiplatelet agent.

Riley AB, Tafreshi MJ, Haber SL.

Am J Health Syst Pharm. 2008 Jun 1;65(11):1019-28. doi: 10.2146/ajhp070496. Review.

PMID:
18499874
8.

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

Scott DM, Norwood RM, Parra D.

Ann Pharmacother. 2009 Jan;43(1):64-76. doi: 10.1345/aph.1G726. Epub 2008 Dec 2. Review.

PMID:
19050170
9.

Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.

Dobesh PP.

Pharmacotherapy. 2009 Sep;29(9):1089-102. doi: 10.1592/phco.29.9.1089.

PMID:
19698014
10.

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators.

Circulation. 2005 Jun 28;111(25):3366-73. Epub 2005 Jun 20.

11.

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators.

Circulation. 2007 Dec 18;116(25):2923-32. Epub 2007 Dec 3.

12.

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators.

Am Heart J. 2006 Oct;152(4):627-35.

PMID:
16996826
13.

Clinical profile of prasugrel, a novel thienopyridine.

Angiolillo DJ, Bates ER, Bass TA.

Am Heart J. 2008 Aug;156(2 Suppl):S16-22. doi: 10.1016/j.ahj.2008.06.005. Review.

PMID:
18657682
14.

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.

Niitsu Y, Sugidachi A, Ogawa T, Jakubowski JA, Hashimoto M, Isobe T, Otsuguro K, Asai F.

Eur J Pharmacol. 2008 Jan 28;579(1-3):276-82. Epub 2007 Oct 11.

PMID:
17996866
15.

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.

Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A.

Eur Heart J. 2008 Jan;29(1):21-30. Epub 2007 Nov 30.

PMID:
18055486
16.

Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.

Tcheng JE, Mackay SM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):83-91. doi: 10.2165/11594600-000000000-00000. Review.

PMID:
22316323
17.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
18.

Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

Thomas D, Giugliano RP.

Crit Pathw Cardiol. 2009 Mar;8(1):12-9. doi: 10.1097/HPC.0b013e318196bb46. Review.

PMID:
19258833
19.

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Capranzano P, Ferreiro JL, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4. Review.

PMID:
19379060
20.

Prasugrel: a novel platelet ADP P2Y receptor antagonist.

Wilson W, Gurvitch R, Ajani AE.

Cardiovasc Ther. 2009 Fall;27(3):194-8. doi: 10.1111/j.1755-5922.2009.00086.x. Review.

PMID:
19689619

Supplemental Content

Support Center